JP2021533795A5 - - Google Patents

Info

Publication number
JP2021533795A5
JP2021533795A5 JP2021509223A JP2021509223A JP2021533795A5 JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5 JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021509223 A JP2021509223 A JP 2021509223A JP 2021533795 A5 JP2021533795 A5 JP 2021533795A5
Authority
JP
Japan
Prior art keywords
sequence
aav
gpr108
polypeptide
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533795A (ja
JP7451497B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/047546 external-priority patent/WO2020041498A1/en
Publication of JP2021533795A publication Critical patent/JP2021533795A/ja
Publication of JP2021533795A5 publication Critical patent/JP2021533795A5/ja
Application granted granted Critical
Publication of JP7451497B2 publication Critical patent/JP7451497B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509223A 2018-08-21 2019-08-21 アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法 Active JP7451497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862720859P 2018-08-21 2018-08-21
US62/720,859 2018-08-21
PCT/US2019/047546 WO2020041498A1 (en) 2018-08-21 2019-08-21 Compositions and methods for modulating transduction efficiency of adeno-associated viruses

Publications (3)

Publication Number Publication Date
JP2021533795A JP2021533795A (ja) 2021-12-09
JP2021533795A5 true JP2021533795A5 (enExample) 2022-07-25
JP7451497B2 JP7451497B2 (ja) 2024-03-18

Family

ID=69591093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509223A Active JP7451497B2 (ja) 2018-08-21 2019-08-21 アデノ随伴ウイルスの形質導入効率を調節するための組成物および方法

Country Status (5)

Country Link
US (1) US12195745B2 (enExample)
EP (1) EP3841109A4 (enExample)
JP (1) JP7451497B2 (enExample)
AU (1) AU2019325332B2 (enExample)
WO (1) WO2020041498A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278598B2 (en) 2018-05-11 2025-11-01 Massachusetts Eye & Ear Infirmary Altering tissue tropism of adeno-associated viruses
CA3153972A1 (en) 2019-09-09 2021-03-18 Massachusetts Eye And Ear Infirmary Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav
WO2021205028A1 (en) 2020-04-09 2021-10-14 University Of Sheffield Gene therapy treatment
US20230295658A1 (en) * 2020-11-10 2023-09-21 The Children's Hospital Of Philadelphia Compositions and methods for in vivo gene transfer
TW202325840A (zh) * 2021-08-30 2023-07-01 美商艾維克羅姆公司 與人肝臟嵌合性組合的腺相關病毒受體（ａａｖｒ）剔除小鼠及彼之使用方法和產製
GB202215198D0 (en) 2022-10-14 2022-11-30 Univ Sheffield Gene therapy treatment
EP4762358A1 (en) 2023-11-30 2026-06-24 Cytomos Limited Cell selection
WO2025188755A1 (en) 2024-03-04 2025-09-12 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
CN118207258A (zh) * 2024-03-12 2024-06-18 浙江恒驭生物科技有限公司 一种检测腺相关病毒转导滴度的敏感细胞系、构建方法及其应用
WO2025226842A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Expression control by drg-expressed mirnas
WO2025226841A1 (en) 2024-04-24 2025-10-30 Kate Therapeutics, Inc. Gene therapy approach for treating disorders associated with tnnt2
WO2026011008A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Expression control by skeletal muscle-expressed mirnas
WO2026011009A1 (en) 2024-07-02 2026-01-08 Kate Therapeutics, Inc. Compositions and methods for muscle disorders
WO2026030242A1 (en) 2024-07-29 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
WO2026030244A1 (en) 2024-07-30 2026-02-05 Kate Therapeutics, Inc. Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
WO2026050402A1 (en) 2024-08-29 2026-03-05 Kate Therapeutics, Inc. Liver de-targeted muscle tropic capsids

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
EP1572893B1 (en) 2001-11-09 2009-01-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES Production of adeno-associated virus in insect cells
SI1496944T1 (sl) * 2002-05-01 2009-02-28 Univ Florida Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov
US20060166363A1 (en) * 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
DE23193606T1 (de) * 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
WO2014124282A1 (en) * 2013-02-08 2014-08-14 The Trustees Of The University Of Pennsylvania Enhanced aav-mediated gene transfer for retinal therapies
WO2016065001A1 (en) * 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
US10081659B2 (en) * 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
US10633662B2 (en) 2015-11-10 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating AAV infection
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017197355A2 (en) * 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
HUE053747T2 (hu) * 2016-08-15 2021-07-28 Genzyme Corp Eljárások AAV kimutatására
US20230048025A1 (en) * 2016-12-22 2023-02-16 Oregon Health & Science University Adeno associated viral vectors
US20210292373A1 (en) 2018-07-10 2021-09-23 University Of Florida Research Foundation, Incorporated Aav vp1u chimeras
TWI862583B (zh) * 2019-04-26 2024-11-21 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼

Similar Documents

Publication Publication Date Title
US12534717B2 (en) AAV capsid proteins for nucleic acid transfer
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2022190081A5 (enExample)
Kohlbrenner et al. Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system
JP2020019772A5 (enExample)
IL317938A (en) Recombinant viral vectors with altered tropism and their uses for the targeted introduction of genetic material into human cells
KR20250025387A (ko) Aav 캡시드 변이체 및 이의 용도
JP2020532981A5 (enExample)
JP2020519284A5 (enExample)
JP2022524434A5 (enExample)
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
JP7688572B2 (ja) ガラクトース血症の処置のための遺伝子治療
JP2022525302A5 (enExample)
JP2020533973A (ja) 改変されたホスホリパーゼドメインを含むアデノ随伴ウイルス（ａａｖ）
KR20250007619A (ko) 신규 재조합 aav vp2 융합 폴리펩티드
US20250340621A1 (en) Methods of aav therapy
JP2020519294A5 (enExample)
JP2024509251A5 (enExample)
US20260131024A1 (en) Gene therapy for prader willi syndrome
US20240318198A1 (en) Gene therapy for angelman syndrome
AR129387A1 (es) Composiciones y métodos para el tratamiento de deficiencias auditivas no asociadas a la edad en un sujeto humano
RU2024111148A (ru) Вирусные частицы, перенацеленные на скелетные мышцы
EP4671264A1 (en) AAV PLASMIDES COMPRISING AN ACCESSORY PROTEIN CODING SEQUENCE
HK40048783A (en) New avv capsid proteins for nucleic acid transfer
RU2019143489A (ru) УСИЛИВАЮЩИЕ АГЕНТЫ ДЛЯ ПОВЫШЕНИЯ ТРАНСФЕКЦИИ КЛЕТОК И/ИЛИ ПРОДУКЦИИ ВЕКТОРА rAAV